Pyc Therapeutics
Clinical trials sponsored by Pyc Therapeutics, explained in plain language.
-
New eye injection targets inherited blindness in early safety trial
Disease control OngoingThis study is testing a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that causes vision loss (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose,…
Phase: PHASE1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
Experimental eye drug aims to halt rare blindness
Disease control OngoingThis study tests an experimental drug called VP-001 for people with a rare inherited eye disease that causes vision loss. The drug is injected into the eye to see if it is safe and can slow down damage to the retina. About 17 adults who have already received VP-001 in earlier stu…
Phase: PHASE1, PHASE2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
Scientists track rare eye disease to pave way for future treatments
Knowledge-focused OngoingThis study follows 50 people with a rare inherited eye condition called PRPF31-related retinal dystrophy (RP11) to see how their vision and eye structure change over time. Researchers will use eye exams, imaging, and patient questionnaires to track these changes. The goal is to b…
Sponsor: PYC Therapeutics • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:05 UTC